SGLT-2 Therapy Center

Study focuses on elevation of amylase and lipase levels as predictors of pancreatitis.

When it comes to antidiabetic therapies, professionals should be aware of safety concerns with concentrated insulin formulations, metformin and renal function, and SGLT-2 inhibitors and DKA. See the breakdown of these safety issues by Tom Palma, RPh, MS, BCPS, and Greg Wiggers, PharmD, PhD, plus exclusive commentary by DIC Advisory Board member Dr. George Bakris.

Are we experiencing the next “magic bullet” in type 2 diabetes?

Study reported SGLT2 Inhibitors monotherapy might not lead to DKA events as opposed to insulin therapy.

In this week's Homerun Slides, understanding the need for cultural competence and the strategies to overcome cultural barriers.

Study answers question of just how effective is a SGLT-2 inhibitor with metformin.

In this week's Homerun Slides, the safety warnings, precautions, and incorporation of SGLT-2 inhibitors into diabetes treatment.

New dual drug could be a diabetes breakthrough.

Even though amputation is not a major effect, it is still important to let patients know about it and how to prevent it with proper foot care.

In this week's Homerun Slides, talking to patients about SGLT-2 as a treatment option.